


Study on the Role of Core 3 O-glycans in Colorectal Cancer using Cell Models



Office of Biotechnology Products (OBP), Center for Drug Evaluation and Research (CDER), Food and Drug Administration, Silver Spring, MD 20993

*Current Address: Vaccine Production Program, Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892



Abstract

O-GalNAc glycosylation, also known as mucin-type O-glycosylation (O-glycosylation) which is characterized by α -GalNAc linked to Serine, Threonine or Tyrosine residues in proteins is one major type of protein glycosylation. The O-glycans on glycoproteins play important roles in many biological processes. The common O-glycans are either Core-1, Gal β 1-3GalNAc- α -R or Core-3, GlcNAc β 1-3GalNAc- α -R based structures. Core-1 O-glycans are the most predominant ones found in all animal cells, while Core-3 O-glycans appear to be restricted to proteins from epithelial cells of gastrointestinal tract. Notably, the Core-3 O-glycans were reportedly to play significant suppressive roles in colorectal tumor biology. The mechanisms underlying Core-3 O-glycans' tumor suppression, however, are not well understood. Core-3 N-acetylglucosaminyltransferase gene (*C3GnT*, β 3*GnT6*) encodes the enzyme responsible for the initiation of Core-3 O-glycan biosynthesis. It is not known how *C3GnT* in intestinal epithelial cells is transcriptionally regulated. Furthermore, existing cell lines do not express *C3GnT*, and how the *C3GnT* is suppressed in colorectal cancer remains elusive. Herein, we firstly established and characterized three colorectal tumor cell lines with the expression of *C3GnT*. Ectopic expression of *C3GnT* eliminated the expression of Tn antigens in the *Cosmc*-deficient cells and led to synthesize Core-3 O-glycans as evidenced by CORA (Cellular O-glycome Reporter/Amplification). Furthermore, expression of *C3GnT* in *Cosmc*-deficient colorectal cancer cell lines caused inhibition of cell growth and migration. Moreover, exogenously expression of *CDX1* and *CDX2*, potential transcription factors for *C3GnT*, resulted in the elevated expression of *C3GnT* thereby decreased expression of Tn antigens in the *Cosmc*-deficient cells. Our ongoing studies will further address the mechanisms for how the suppression of *C3GnT* and loss of core-3 O-glycans lead to the progression and metastasis of human colorectal carcinoma. Overall, this study will lead to our better understanding of important role of *C3GnT* in colon cancer, and the development of potential therapeutics.

Summary

1. Ectopic overexpression of *C3GnT* eliminated the expression of Tn antigens in the *Cosmc*-deficient cells, and led to synthesize an array of Core-3 O-glycans.
2. Expression of *C3GnT* in *Cosmc*-deficient colorectal cancer cell lines caused inhibition of cell growth and migration.
3. Exogenously expression of *CDX1* and/or *CDX2*, potential transcription factors for *C3GnT*, resulted in the expression of *C3GnT* thereby decreased expression of Tn antigens in the *Cosmc*-deficient cells.

Results

Overexpression of *C3GnT* in *Cosmc*-KO cells resulted in significantly reduced expression of Tn antigens




Figure 1: Ectopic overexpression of *C3GnT* resulted in significantly reduced cell-surface expression of Tn antigen. Expression of *C3GnT* (green) and Tn antigen (red) in sorted *Cosmc*-KO cells were immunofluorescently stained. Nuclei were counterstained with DAPI (blue).

Overexpression of *C3GnT* in *Cosmc*-KO cells resulted in inhibition of cell growth and migration




Figure 3: Effects of *C3GnT* overexpressing on the growth and migration of colorectal cancer cells in vitro. (A) Cell count assays were performed to analyze the effect of *C3GnT* overexpressing on colorectal cancer cell growth in vitro. (B) Wound healing assay was made in cell lines with 48 hours of recovery.

FDA Mission Relevance

Our research advances better understanding of important role of *C3GnT* in colon cancer that can help development of potential therapeutics to predict patient response to the targeted therapies. The acquired information also has implications in helping the FDA reviewers in making more informed regulatory decisions regarding specific drug combination strategies and interpretation of clinical safety and efficacy data.

Overexpression of *C3GnT* resulted in production of Core 3-based O-Glycans




Figure 2: Ectopic overexpression of *C3GnT* led to synthesize an array of Core-3 O-glycans as confirmed by mass spectrometry (MS) analysis.

Overexpression of Transcription Factor *CDX1* and/or *CDX2* in *Cosmc*-KO cells resulted in expression of *C3GnT*




Figure 4: Ectopic overexpression of *CDX1* and *CDX2* in *Cosmc*-KO cells resulted in significantly increased expression of *C3GnT*. Expression of *C3GnT* (green) and Tn antigen (red) cells were immunofluorescently stained. Nuclei were counterstained with DAPI (blue).

Further Directions

1. The role of *C3GnT* in human colorectal carcinoma:
 - ❖ The link between suppression of *C3GnT* and Tn antigen expression in the progression and metastasis of human colorectal carcinoma.
 - ❖ The expression status of *C3GnT* in human primary CRC samples.
2. The mechanisms for how the suppression of *C3GnT* and loss of core-3 O-glycans lead to the progression and metastasis of human colorectal carcinoma.